GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dizal (Jiangsu) Pharmaceutical Co Ltd (SHSE:688192) » Definitions » ROE %

Dizal (Jiangsu) Pharmaceutical Co (SHSE:688192) ROE % : -73.84% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Dizal (Jiangsu) Pharmaceutical Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Dizal (Jiangsu) Pharmaceutical Co's annualized net income for the quarter that ended in Jun. 2024 was ¥-482.1 Mil. Dizal (Jiangsu) Pharmaceutical Co's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was ¥652.8 Mil. Therefore, Dizal (Jiangsu) Pharmaceutical Co's annualized ROE % for the quarter that ended in Jun. 2024 was -73.84%.

The historical rank and industry rank for Dizal (Jiangsu) Pharmaceutical Co's ROE % or its related term are showing as below:

SHSE:688192' s ROE % Range Over the Past 10 Years
Min: -102.36   Med: -57.28   Max: -31.94
Current: -102.36

During the past 6 years, Dizal (Jiangsu) Pharmaceutical Co's highest ROE % was -31.94%. The lowest was -102.36%. And the median was -57.28%.

SHSE:688192's ROE % is ranked worse than
91.91% of 964 companies
in the Drug Manufacturers industry
Industry Median: 4.275 vs SHSE:688192: -102.36

Dizal (Jiangsu) Pharmaceutical Co ROE % Historical Data

The historical data trend for Dizal (Jiangsu) Pharmaceutical Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dizal (Jiangsu) Pharmaceutical Co ROE % Chart

Dizal (Jiangsu) Pharmaceutical Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -89.69 -76.72 -37.83 -34.87 -84.98

Dizal (Jiangsu) Pharmaceutical Co Quarterly Data
Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -75.34 -103.65 -115.50 -116.09 -73.84

Competitive Comparison of Dizal (Jiangsu) Pharmaceutical Co's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Dizal (Jiangsu) Pharmaceutical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dizal (Jiangsu) Pharmaceutical Co's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dizal (Jiangsu) Pharmaceutical Co's ROE % distribution charts can be found below:

* The bar in red indicates where Dizal (Jiangsu) Pharmaceutical Co's ROE % falls into.



Dizal (Jiangsu) Pharmaceutical Co ROE % Calculation

Dizal (Jiangsu) Pharmaceutical Co's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-1107.713/( (1758.481+848.627)/ 2 )
=-1107.713/1303.554
=-84.98 %

Dizal (Jiangsu) Pharmaceutical Co's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Mar. 2024 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=-482.064/( (696.593+609.058)/ 2 )
=-482.064/652.8255
=-73.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.


Dizal (Jiangsu) Pharmaceutical Co  (SHSE:688192) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-482.064/652.8255
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-482.064 / 488.928)*(488.928 / 1598.604)*(1598.604 / 652.8255)
=Net Margin %*Asset Turnover*Equity Multiplier
=-98.6 %*0.3058*2.4487
=ROA %*Equity Multiplier
=-30.15 %*2.4487
=-73.84 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-482.064/652.8255
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-482.064 / -832.248) * (-832.248 / -821.588) * (-821.588 / 488.928) * (488.928 / 1598.604) * (1598.604 / 652.8255)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.5792 * 1.013 * -168.04 % * 0.3058 * 2.4487
=-73.84 %

Note: The net income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Dizal (Jiangsu) Pharmaceutical Co ROE % Related Terms

Thank you for viewing the detailed overview of Dizal (Jiangsu) Pharmaceutical Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Dizal (Jiangsu) Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Jinghui East Road, Room 4105, Building E (Building 5), Huirong Business Plaza, Xinwu District, Jiangsu Province, Wuxi City, CHN, 201203
Dizal (Jiangsu) Pharmaceutical Co Ltd is engaged in the research and development, production and sales of innovative drugs.
Executives
Wu Qing Yi senior management
Lv Hong Bin senior management
Directors, senior managers
Directors, senior managers, core technical personn
Senior management, core technical personnel
Zheng Li Core technical personnel
Yang Zhen Fan Senior management, core technical personnel
Senior management, core technical personnel
Qiao Wei Jun Core technical personnel
Chen Kan Core technical personnel
Chen Su Qin Senior management, core technical personnel
Zhang Zhi Wei senior management
Senior management, core technical personnel
Senior management, core technical personnel

Dizal (Jiangsu) Pharmaceutical Co Headlines

No Headlines